Proportion of patients meeting quality indicators for care of early-stage chronic kidney disease among First Nations people and other people in Ontario as of Sept. 30, 2015
| Group; indicator | No. (%) of people* | p value | |
|---|---|---|---|
| First Nations people | Other people in Ontario | ||
| Initial eGFR < 60 mL/min per 1.73 m2 | |||
| Repeat outpatient serum creatinine test within 6 mo | 246/554 (44.4) | 23 371/50 249 (46.5) | 0.3 |
| Outpatient ACR test within 6 mo | 100/554 (18.0) | 11 956/50 249 (23.8) | 0.001 |
| Initial ACR > 3 mg/mmol | |||
| Repeat outpatient ACR test within 6 mo | 312/2018 (15.5) | 22 875/95 765 (23.9) | < 0.001 |
| Chronic kidney disease | |||
| Outpatient serum creatinine test in following 18 mo | 327/443 (73.8) | 42 740/53 559 (79.8) | 0.002 |
| Outpatient ACR test in following 18 mo | 182/443 (41.1) | 26 797/53 559 (50.0) | < 0.001 |
| Not prescribed an NSAID for longer than 2 wk in following 12 mo† | 772/859 (89.9) | 111 720/127 008 (88.0) | 0.09 |
| Not prescribed an ACE inhibitor and ARB simultaneously in following 12 mo† | 840/859 (97.8) | 125 536/127 008 (98.8) | 0.009 |
| ACE inhibitor or ARB prescription in following 12 mo† | 686/859 (79.9) | 101 032/127 008 (79.5) | 0.9 |
| Statin prescription in following 12 mo‡ | 502/652 (77.0) | 61 667/77 741 (79.3) | 0.2 |
| Serum potassium test 7–30 d after initial ACE inhibitor/ARB prescription† | 8/46 (17.4) | 1134/8584 (13.2) | 0.4 |
| Serum creatinine test 7–30 d after initial ACE inhibitor/ARB prescription† | 8/46 (17.4) | 1298/8584 (15.1) | 0.7 |
| Initially meeting criteria for referral to nephrologist | |||
| Visit to nephrologist within 180 d after referral eligibility date | 136/672 (20.2) | 5687/27 611 (20.6) | 0.9 |
| Visit to nephrologist within 365 d after referral eligibility date | 170/545 (31.2) | 6725/23 210 (29.0) | 0.3 |
Note: ACE = angiotensin-converting enzyme, ACR = albumin-to-creatinine ratio, ARB = angiotensin II receptor blocker, eGFR = estimated glomerular filtration rate, NSAID = nonsteroidal anti-inflammatory drug.
↵* The number of people in the denominators/subcohorts for each indicator varied based on the amount of look-forward period needed to assess the indicator. For example, indicators requiring 18 months of follow-up time included eligible patients with laboratory values to define the subcohorts on or before Mar. 30, 2014, with follow-up to Sept. 30, 2015; indicators that required only 1-year follow-up included eligible patients with laboratory values to define the subcohorts on or before Sept. 30, 2014, with follow-up to Sept. 30, 2015.
↵† Only among people 65 years of age or more.
↵‡ Only among people 65–80 years of age.